Connect your AI

Annexon ANNX Change in Other Assets

Change in Other Assets at other companies

Dianthus TherapeuticsDNTH

$2.33M+21.9%

OmerosOMER

-$87K-118%

Vor BiopharmaVOR

$6.36M+2,653%

Cullinan Therapeutics, Inc.CGEM

$662K+138%

Nektar TherapeuticsNKTR

-$949K-116%

AnaptysBio, Inc.ANAB

-$1.5M-183%

Other financials

Income statement

Operating income-$46.1M+19.8%

Net income-$44.1M+18.8%

EPS (diluted)-$0.23+37.8%

Balance sheet

Cash & equivalents$175.2M+80.4%

Total debt$25.4M-10.2%

Total equity$204.5M-16.1%

Total assets$262.9M-13.2%

Cash flow

Operating cash flow-$46.8M+6.5%

CapEx--100%

Free cash flow-$46.8M+6.6%

Valuation

Market cap$868.37M+223%

Enterprise value$718.59M+261%

Returns & leverage

Return on equity-87.6%+42.3pp

Debt / equity0.1×0.0×

Current ratio6.4×-1.6×

Where this comes from

Reported directly by Annexon in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherNoncurrentAssets.

The official record: Annexon’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Annexon's change in other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Annexon's change in other assets?: Annexon (ANNX) reported change in other assets of -$275K in Q1 2026.
How has Annexon's change in other assets changed year-over-year?: Annexon's change in other assets decreased by 113.5% year-over-year, from $2.03M to -$275K.
What does change in other assets mean?: Change in miscellaneous assets affecting operating cash flow.